#Switzerland #Neurimmune #NovaGo Therapeutics #Schlieren #Pureos Bioventures

NovaGo Therapeutics' Milestone Funding Round

In a significant advancement for spinal cord injury research, NovaGo Therapeutics AG, a pioneering clinical-stage biotechnology company, has announced the successful completion of a Series B financing round, raising $30 million (24 million CHF). This funding initiative, led by prominent investors Neurimmune and Pureos Bioventures, aims to propel their innovative Proof-of-Concept (PoC) study for patients suffering from acute spinal cord injuries.

The financing received additional support from the Swiss Paraplegic Foundation and Wings for Life – Spinal Cord Research Foundation. These non-dilutive funding measures emphasize the urgent need for effective treatments in a field long underrepresented in regenerative medicine.

Addressing Unmet Medical Needs

Spinal cord injuries represent a significant medical challenge, with very few solutions currently available to restore lost neurological functions. With no approved regenerative therapies in sight, patients and their families are often left with limited options post-injury. NovaGo's approach focuses on targeting Nogo-A, a protein known to inhibit nerve fiber regeneration and neuroplasticity in the central nervous system. The goal is to promote meaningful recovery by disrupting these inhibitory signals.

Professor Martin Schwab, the Chief Scientific Officer at NovaGo Therapeutics, expressed optimism about this program entering such a critical phase of clinical trials, stating, "This brings us a significant step closer to providing a much-needed treatment approach for patients living with the consequences of spinal cord injuries."

Novel Therapeutic Strategies

The $30 million infusion of capital will primarily focus on advancing NovaGo's lead program into a fully randomized, double-blind PoC study involving 120 patients across clinical sites in Germany, Spain, and Switzerland. This study’s design aims to ensure robust data collection that could lay the groundwork for future treatments.

Neurimmune’s President and CEO, Professor Roger M. Nitsch, highlighted the novelty of their therapeutic strategy, stating, "Together with NovaGo Therapeutics, we are unlocking a new paradigm in treating spinal cord injuries using a fully human therapeutic antibody that aims to promote nerve growth post-injury."

Promising Early Results

The enthusiasm for this funding round is bolstered by encouraging early results from Phase 1 studies involving NovaGo’s lead compound, NG004. These findings have generated significant excitement among investors and stakeholders, increasingly viewing NovaGo as a frontrunner in Nogo-A-related therapies. Dominik Escher, Managing Partner at Pureos Bioventures, shared his perspective on the investment, affirming that they are committed to supporting NovaGo through its next developmental phase.

A Collaborative Future

NovaGo Therapeutics' CEO, Stefan Moese, acknowledged the crucial role played by their investors, stating, "We are deeply grateful for the support of our investors, and the contributions from Wings for Life and the Swiss Paraplegic Foundation have been vital in facilitating this important development phase."

The combined expertise and foresight from NovaGo Therapeutics, Neurimmune, and Pureos Bioventures create a powerful collaboration aimed at advancing spinal cord injury treatments. The ultimate goal is to provide effective therapeutic solutions to patients enduring the devastating impacts of spinal cord injuries, heralding a potential new era in regenerative therapy.

About the Companies

Pureos Bioventures: As a venture fund advised by Swiss investment company Pureos Partners, it specializes in investing in private innovative drug development companies, particularly those pioneering next-generation biologics.

Neurimmune: This clinical-stage biopharmaceutical company focuses on developing next-generation antibody therapeutics, addressing challenges in central nervous system diseases.

NovaGo Therapeutics: This clinical-stage biotechnology company specializes in novel Anti-Nogo-A biologics to promote nerve regeneration and functional recovery in patients suffering from central nervous system diseases, including spinal cord injuries.

Through their focused efforts, these organizations are set to make groundbreaking strides in a field desperately in need of innovation.